Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE, Baumgartner F, Heider M, Patra U, Holz M, Braune J, Kaiser M, Schäffer I, Bamopoulos SA, Ramberger E, Murgai A, Ng YLD, Demel UM, Laue D, Liebig S, Krüger J, Janz M, Nogai A, Schick M, Mertins P, Müller S, Bassermann F, Krönke J, Keller U, Wirth M. Heynen GJJE, et al. Among authors: schick m. Blood Adv. 2023 Feb 28;7(4):469-481. doi: 10.1182/bloodadvances.2022007875. Blood Adv. 2023. PMID: 35917568 Free PMC article.
Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma.
Scherger AK, Al-Maarri M, Maurer HC, Schick M, Maurer S, Öllinger R, Gonzalez-Menendez I, Martella M, Thaler M, Pechloff K, Steiger K, Sander S, Ruland J, Rad R, Quintanilla-Martinez L, Wunderlich FT, Rose-John S, Keller U. Scherger AK, et al. Among authors: schick m. JCI Insight. 2019 Aug 8;4(15):e128435. doi: 10.1172/jci.insight.128435. eCollection 2019 Aug 8. JCI Insight. 2019. PMID: 31391340 Free PMC article.
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. Biederstädt A, et al. Among authors: schick m. Gut. 2020 Aug;69(8):1472-1482. doi: 10.1136/gutjnl-2018-317856. Epub 2020 Jan 30. Gut. 2020. PMID: 32001555 Free PMC article.
The SUMO pathway in pancreatic cancer: insights and inhibition.
Schneeweis C, Hassan Z, Schick M, Keller U, Schneider G. Schneeweis C, et al. Among authors: schick m. Br J Cancer. 2021 Feb;124(3):531-538. doi: 10.1038/s41416-020-01119-6. Epub 2020 Oct 19. Br J Cancer. 2021. PMID: 33071285 Free PMC article. Review.
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
Lewis R, Maurer HC, Singh N, Gonzalez-Menendez I, Wirth M, Schick M, Zhang L, Isaakidis K, Scherger AK, Schulze V, Lu J, Zenz T, Steiger K, Rad R, Quintanilla-Martinez L, Espeli M, Balabanian K, Keller U, Habringer S. Lewis R, et al. Among authors: schick m. Leukemia. 2021 Oct;35(10):2895-2905. doi: 10.1038/s41375-021-01376-1. Epub 2021 Aug 6. Leukemia. 2021. PMID: 34363012 Free PMC article.
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde-Rajaratnam M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F. Stroh J, et al. Among authors: schick m. Blood Adv. 2022 Jan 25;6(2):515-520. doi: 10.1182/bloodadvances.2021005532. Blood Adv. 2022. PMID: 34768284 Free PMC article.
408 results